AllSci News

Systematic, data-driven science coverage · Monday, September 14, 2026
The AllSci BriefFree, systematic R&D and deal news. Daily.
Most Read
Development

NeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor

NeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor
Regulatory & Policy

FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027

FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027
Development

Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I

Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I
Business

Exegenesis and Modalis combine muscle-targeting AAV with epigenome editing for preclinical DMD candidate

Exegenesis and Modalis combine muscle-targeting AAV with epigenome editing for preclinical DMD candidate
Development

OMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia

OMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia
Editor’s Picks
Teva raises USD 4.9bn to refinance higher-coupon debtBusiness

Teva raises USD 4.9bn to refinance higher-coupon debt

· 1 min read
IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancerBusiness

IMUNON partners with National Cancer Institute to expand IL-12 DNA plasmid beyond ovarian cancer

· 2 min read
Exegenesis and Modalis combine muscle-targeting AAV with epigenome editing for preclinical DMD candidateBusiness

Exegenesis and Modalis combine muscle-targeting AAV with epigenome editing for preclinical DMD candidate

· 2 min read
Latest NewsView all news →
Yarrow raises USD 150m to advance first-in-class Graves' disease antibody into Phase II
Business

Yarrow raises USD 150m to advance first-in-class Graves' disease antibody into Phase II

Connecticut-based Yarrow Bioscience, Inc. (Nasdaq: YARW) announced the pricing of an underwritten public offering of 5,769,231 shares of common stock at USD...

3d agoNeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor
Development

NeuroHarmonics launches first patient trial of non-invasive deep-brain ultrasound for essential tremor

London-based neurotechnology company NeuroHarmonics is set to begin recruiting patients for the first clinical evaluation of its non-invasive deep-brain...

3d agoGan & Lee advances once-weekly oral GLP-1 peptide into Phase I
Development

Gan & Lee advances once-weekly oral GLP-1 peptide into Phase I

China-based Gan & Lee Pharmaceuticals Co., Ltd. has dosed the first participant in a Phase I study of GZC8072, an oral peptide glucagon-like peptide-1...

3d agoJohns Hopkins tests pancreatic TLR4–hyperglycemia axis as driver of necrotizing enterocolitis
Discovery

Johns Hopkins tests pancreatic TLR4–hyperglycemia axis as driver of necrotizing enterocolitis

Johns Hopkins University has received a USD 2.5 million NIH R01 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to...

3d agoFDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027
Regulatory & Policy

FDA extends Exelixis' zanzalintinib review by three months, pushing decision to March 2027

The US FDA has extended its review of the New Drug Application (NDA) for zanzalintinib, an oral kinase inhibitor, in combination with atezolizumab...

3d agoOMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia
Development

OMass enters human testing with MC2R antagonist OMS1620 for congenital adrenal hyperplasia

UK-based OMass Therapeutics has registered a Phase I trial of OMS1620, an oral small-molecule melanocortin-2 receptor (MC2R) antagonist being developed for...

3d agoNavion Neurosciences secures USD 10.8m to pursue sodium-channel drugs for epilepsy and pain
Business

Navion Neurosciences secures USD 10.8m to pursue sodium-channel drugs for epilepsy and pain

Charlottesville, Virginia-based Navion Neurosciences, Inc. announced first closing of a USD 10.8 million seed financing round to advance precision...

3d agoFDA grants Fast Track Designation to Sobi's pacritinib for VEXAS syndrome
Regulatory & Policy

FDA grants Fast Track Designation to Sobi's pacritinib for VEXAS syndrome

Swedish Orphan Biovitrum AB (Stockholm: SOBI), operating through its North American affiliate Sobi North America, announced that the US FDA has granted Fast...

3d ago
The AllSci BriefFree, systematic R&D and deal news. Daily.
Encoded Therapeutics raises USD 275m to push ETX101 toward pivotal Dravet syndrome trial
Business

Encoded Therapeutics raises USD 275m to push ETX101 toward pivotal Dravet syndrome trial

South San Francisco-based Encoded Therapeutics has closed a USD 275 million Series F financing round to advance its lead gene therapy candidate through...

3d agoCONNECTA raises EUR 3.1m to advance TrkB modulator into mid-stage Fragile X trial
Business

CONNECTA raises EUR 3.1m to advance TrkB modulator into mid-stage Fragile X trial

Barcelona-based CONNECTA Therapeutics has closed a EUR 3.1 million (USD 3.4 million) financing round to support the clinical development of CTH120, its...

3d agoEthris secures EUR 30m to advance broad-spectrum nasal antiviral into Phase IIb trials
Business

Ethris secures EUR 30m to advance broad-spectrum nasal antiviral into Phase IIb trials

Germany-based Ethris GmbH has secured EUR 30 million to support the advance of its mRNA-based respiratory treatments into later-stage trials. The financing...

3d agoCerenome secures USD 20m royalty-based financing to scale CNSide diagnostics platform
Business

Cerenome secures USD 20m royalty-based financing to scale CNSide diagnostics platform

Houston-based Cerenome, Inc. (Nasdaq: CNSY) has secured a senior secured financing facility of up to USD 20 million from 3i, LP, structured with...

3d agoThird Arc Bio advances first masked CD3 TCE under expanded Adagene collaboration
Business

Third Arc Bio advances first masked CD3 TCE under expanded Adagene collaboration

Third Arc Bio has selected its first lead candidate under an amended strategic collaboration with Adagene Inc. (Nasdaq: ADAG), triggering an expansion of...

3d agoFDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track
Development

FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track

A partial clinical hold on opakalim (BHV-7000), Biohaven Ltd.'s (NYSE: BHVN) selective Kv7.2/7.3 potassium channel activator in pivotal development for...

3d agoNeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout
Business

NeOnc raises USD 15m to advance Phase II CNS cancer programs after NEO100 efficacy readout

California-based NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) announced a USD 15 million registered direct offering on September 9, 2026, with proceeds...

3d ago